drugset / Trial / NCT00064285
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
Phase 1
Completed
22 enrolled
Virginia Commonwealth University
National Cancer Institute (NCI) · collab
Non-randomizedFactorialOpen-labelTreatment
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with flavopiridol may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and imatinib mesylate in treating patients with hematologic cancer.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | Oral |
| Subject | alvocidib | Small molecule | — | Intravenous |